comparemela.com

Latest Breaking News On - Pertinence invest - Page 1 : comparemela.com

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners | Antibodies

Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Merieux Equity Partners

Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Merieux Equity Partners
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.

Investegate |Mablink Bioscience Announcements | Mablink Bioscience: Mablink Bioscience announces a 31 million Series A

Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs)Its proprietary ADC technology opens the door

AcuSurgical raises €5 75 Million in Series A financing, to advance its robotic ocular microsurgery platform

Press release content from Business Wire. The AP news staff was not involved in its creation. AcuSurgical raises €5.75 Million in Series A financing, to advance its robotic ocular microsurgery platform. February 18, 2021 GMT MONTPELLIER, France (BUSINESS WIRE) Feb 18, 2021 AcuSurgical, a Montpellier-based company focused on robotic microsurgery, today announces a €5.75 million Series A financing round led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating in the round. ADVERTISEMENT Using advanced robotics, AcuSurgical is making ocular microsurgery safer and more accessible by dramatically improving the precision of surgical interventions. A proof of concept of the platform has already been completed with a first prototype validated in a preclinical setting.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.